Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
Authors
Keywords
Estrogen receptor (ER)-positive breast cancer, Late recurrence, Extended tamoxifen
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-07
DOI
10.1186/s12885-016-2423-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008
- (2015) Rachel J.D. Cossetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
- (2015) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
- (2014) Mustafa Al-Mubarak et al. PLoS One
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer
- (2013) Kathrin Strasser-Weippl et al. BREAST
- The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
- (2013) P Dubsky et al. BRITISH JOURNAL OF CANCER
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
- (2013) Ivana Sestak et al. JNCI-Journal of the National Cancer Institute
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
- (2013) Dennis C Sgroi et al. LANCET ONCOLOGY
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry
- (2011) Seho Park et al. BREAST
- Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
- (2011) Judith M. Bliss et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer
- (2009) So-Youn Jung et al. ANNALS OF SURGICAL ONCOLOGY
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
- (2008) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial
- (2008) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started